[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341936-105":59,"doc-detail-341936-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-impact-of-non-structured-psa-testing-on-prostate-cancer-specific-mortality-on-new-zealand-maori-men","The impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand Māori men","","Objectives assessed how differences in Prostate-Specific Antigen (PSA) testing rates affect prostate cancer diagnosis and prostate cancer-specific mortality among Māori men in a New Zealand population. Patients and methods included Māori men aged 40+ without prior prostate cancer who had PSA testing between 2006 and 2018, grouped as a screened cohort versus a non-screened cohort. Cancer diagnoses were measured and competing risk analysis evaluated survival, linking outcomes to testing frequency, grade distribution, and 10-year cancer-specific survival.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-impact-of-non-structured-psa-testing-on-prostate-cancer-specific-mortality-on-new-zealand-maori-men/341936/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-impact-of-non-structured-psa-testing-on-prostate-cancer-specific-mortality-on-new-zealand-maori-men/341936.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",24,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How were screened and non-screened groups defined in the study?","Question",{"text":113,"@type":114},"Māori men with high PSA testing levels were classified as the screened group if they had two or more PSA tests with a rate of one test every four years or less. All other men were included in the non-screened group.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What outcomes were measured to evaluate prostate cancer care differences?",{"text":118,"@type":114},"The study measured prostate cancer diagnosis, including cancer grade, and prostate cancer-specific mortality. Competing risk analysis was used to assess survival.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the study find about PSA testing frequency and prostate cancer-specific death?",{"text":122,"@type":114},"Lower PSA testing rates were associated with a higher risk of prostate cancer-related death. In multivariable modeling, PSA testing frequency independently predicted prostate cancer mortality.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341936,1790102446,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","World Journal of Urology (2024) 42:558  \n[https://doi.org/10.1007/s00345-024-05260-2](https://doi.org/10.1007/s00345-024-05260-2)  \nRESEARCH  \nThe impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand Māori men  \nBashar Matti1 · Cindy H. Nguyen1 · Mataroria P. Lyndon2 · Kamran Zargar-Shoshtari1,3  \nReceived: 17 July 2023 / Accepted: 1 September 2024 / Published online: 3 October 2024 © The Author(s) 2024  \nAbstract  \nObjectives To assess the impact of differences in Prostate-Specific Antigen (PSA) testing rates on prostate cancer (PCa) diagnosis and PCa-specific mortality among Māori men in a New Zealand (NZ) population.  \nPatients and Methods Māori men aged 40 years or older, without a history of PCa, with a PSA test between 2006 and 2018 were included. The cohort was divided into two groups; the “screened group”(ScG) consisting of men who had at least one PSA test every four years or less, and the “non-screened group”(non-SG) . We measured the rate of cancer diagnoses and used competing risk analysis to assess survival.  \nResults The study cohort included 63,939 Māori men, with 37,048 (58%) in the ScG. PCa was more frequently diagnosed in the ScG (3.7% vs. 3.0%, P \u003C0.001) . A higher proportion of high-grade cancers were found in the non-SG (32.7% vs. 25.6%, P = 0.001) . The 10-year cancer-specific survival was significantly higher in the ScG (99.4% vs. 98.5%, P \u003C0.001) . In a multivariable risk model, PSA testing frequency was an independent predictor of PCa mortality. (HR 2.43,[95% CI 1.97–3.01], P \u003C0.001) .  \nConclusions In a cohort of only Māori men, lower PSA testing rates were associated with a higher risk of PCa-related death. Therefore, regular PSA testing for Māori could improve cancer-specific survival among Māori men. Regular PSA testing should be considered a priority area for improving PCa survival in this population.  \nKeywords Prostate-specific antigen · Early detection of cancer · Mass screening · Prostatic neoplasm · Health inequities  \nIntroduction  \nNew Zealand (NZ) has one of the highest incidences of prostate cancer (PCa) in the world (105.2 per 100 000) [1] . Currently, there is no population-based screening program in NZ. Instead there is widespread opportunistic ProstateSpecific Antigen (PSA) testing in NZ and subsequently high rates of PCa detection. Data shows that not all men in NZ have equitable access to PSA testing. In particular, Māori  \n􀀍 Cindy H. Nguyen [cngu539@aucklanduni.ac.nz](cngu539@aucklanduni.ac.nz)  \n1 Department of Surgery, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand  \n2 Faculty of Medical and Health Sciences, Centre for Medical and Health Science Education, University of Auckland, Auckland, New Zealand  \n3 Department of Surgery, Counties Manukau District Health Board, Auckland, New Zealand  \nmen are significantly less likely to receive a PSAtest and are less likely to have regular PSA testing [2] . This lower rate of PSA testing may explain the lower incidence of PCa seen in NZ Māori compared to the NZ European population [1] .  \nThe European Randomized Study of Screening for Prostate Cancer (ERSPC) trial has shown that repeated cycles of PSA testing reduces PCa mortality [3] . On this basis, we hypothesised that the lower rates of PSA testing in Māori are a direct contributor to the worse PCa-specific survival seen in this population. However, to minimise social and cultural confounders that may affect PCa survival, we aimed to assess the impact of regular PSA testing on PCa outcomes (diagnosis and mortality) in a cohort of only Māori men [4] .  \nMethods  \nStudy population  \nThe study population constituted all Māori men who had a PSA test between 1 January 2006 and 1 January 2018. Men with a prior diagnosis of PCa were excluded and assumed to have PSA tests for disease monitoring. We also excluded men younger than 40 because PSA is generally not utilised in PCa screening among these men. Only one PSA tes","cbCaihbrxldac7Pb","https://ap.wps.com/l/cbCaihbrxldac7Pb","pdf",795098,"English","# Abstract\n# Introduction\n# Methods\n## Study population\n## Data sources\n## Outcomes measured\n## Data management and statistical analysis\n# Results\n# Conclusions","[{\"question\":\"How were screened and non-screened groups defined in the study?\",\"answer\":\"Māori men with high PSA testing levels were classified as the screened group if they had two or more PSA tests with a rate of one test every four years or less. All other men were included in the non-screened group.\"},{\"question\":\"What outcomes were measured to evaluate prostate cancer care differences?\",\"answer\":\"The study measured prostate cancer diagnosis, including cancer grade, and prostate cancer-specific mortality. Competing risk analysis was used to assess survival.\"},{\"question\":\"What did the study find about PSA testing frequency and prostate cancer-specific death?\",\"answer\":\"Lower PSA testing rates were associated with a higher risk of prostate cancer-related death. In multivariable modeling, PSA testing frequency independently predicted prostate cancer mortality.\"}]","The impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand Māori men | PDF",1790044403,15,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f674ac07adec026759824794c8ee3833.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c761e2656019b1032af3a80ca008def6.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f95ab7f3b1a7e61a68b1c24ea09da735.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/496e1bc4a391371f60765c992f8eab73.webp",980,1301]